Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Meera Mohan, MD, Samantha Kendrick, PhD, Yadav Pandey, MD, Richa Parikh, MD, Phil Farmer, Mathew Kottarathara, MD, Shadiqul Hoque, MD, Angel Mitma, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Guido Tricot, MD PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139943

Published: 2020

Journal Articles

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Frits van Rhee, MD PhD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Jeffery R. Sawyer, Adam Rosenthal, MS, Doug Steward, Phil Farmer, Robert Smith, Milan Bimali, PhD, Mariam M. Boota, MD, Clyde Bailey, Brian A Walker, PhD, Antje Hoering, PhD, Gareth Morgan, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD

Blood (2019) 134 (Supplement_1): 4569.

https://doi.org/10.1182/blood-2019-131887

Published: 2019

Journal Articles

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Blood (2018) 132 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2018-99-119113

Published: 2018

Journal Articles

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Blood (2018) 132 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2018-99-113169

Published: 2018

Journal Articles

Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches

Christopher Wardell, PhD, Terri Lynn Alpe, Phil Farmer, Michael W Rutherford, Yan Wang, Niels Weinhold, PhD, Ruslana G. Tytarenko, MS, Purvi Patel, Michael A Bauer, PhD, Cody Ashby, PhD, Eileen M Boyle, MD MSc, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Brian A Walker, PhD, Gareth Morgan, MD, Faith E. Davies, MD

Blood (2018) 132 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2018-99-117103

Published: 2018

Journal Articles

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Sandra Susanibar, MD, Pingping Qu, Antje Hoering, Sharmilan Thanendrarajan, MD, Jorge Jo Kamimoto, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Nathan Petty, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD, Daisy Alapat, MD, Barlogie Bart, Gareth J. Morgan, MD PhD, Carolina D. Schinke, MD

Blood (2017) 130 (Supplement 1): 3047.

https://doi.org/10.1182/blood.V130.Suppl_1.3047.3047

Published: 2017

Journal Articles

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Sharmilan Thanendrarajan, MD, Jerry Puryear, PharmD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Pankaj Mathur, MD, Meera Mohan, MD, Sandra Susanibar, MD, Jorge Jo Kamimoto, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Leo Rasche, MD, Niels Weinhold, PhD, Brian A Walker, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 1858.

https://doi.org/10.1182/blood.V130.Suppl_1.1858.1858

Published: 2017

NARROW

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab

Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior

Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies

Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only